The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 14, 2022
Filed:
Apr. 14, 2017
Applicant:
Research Institute AT Nationwide Children's Hospital, Columbus, OH (US);
Inventors:
Louise Rodino-Klapac, E. Groveport, OH (US);
Jerry R. Mendell, Columbus, OH (US);
Assignee:
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, Columbus, OH (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 21/00 (2006.01); C07K 14/47 (2006.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); C12N 15/86 (2006.01); A61P 25/14 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4716 (2013.01); A61K 48/0058 (2013.01); A61K 48/0075 (2013.01); A61P 21/00 (2018.01); A61P 25/14 (2018.01); C07K 14/705 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2800/22 (2013.01); C12N 2830/008 (2013.01);
Abstract
Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising β-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystrophy. Also described herein are combination therapies comprising administering AAV vector(s) expressing β-sarcoglycan and miR-29c to a mammalian subject suffering from a muscular dystrophy.